Page 3 - ஜூ இ News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: Interim Results and Business Updates
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
微纪录片+短视频+直播，总台央视纪录频道联合快手开启中国世界遗产地神奇之旅
sootoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sootoo.com Daily Mail and Mail on Sunday newspapers.
Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: Stabilizing Actions & End of Stabilization Period
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Hutchison China MediTech Limited (AIM:HCM) | RNS | Hutchmed China Ltd
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
Share:
– EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors –
– Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval –
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ( EMA ) has validated and accepted its marketing authorization application ( MAA ) for surufatinib for the treatment of pancreatic and extra-pancreatic (non-pancreatic) neuroendocrine tumors ( NETs ). The EMA s validation confirms that the submission is sufficiently complete and that it is ready to commence the formal review process.